Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059111 | PMC |
| http://dx.doi.org/10.1681/ASN.0000000654 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[The highlights of dialysis in 2024].
Nephrol Ther
April 2025
CHU de Bordeaux, Hôpital Pellegrin, service de néphrologie, transplantation, dialyse et aphérèses, Université de Bordeaux, Inserm, BMC, U1034, Pessac, France
In 2024, dialysis is experiencing advancements, particularly in environmental sustainability. “Green dialysis” is emerging as a priority, aiming to reduce the carbon footprint of dialysis centers (water and resource consumption, patient transportation). Innovative strategies, such as adjusting dialysate flow rate and temperature, have demonstrated similar effectiveness to standard dialysis in terms of Kt/V while reducing water consumption.
View Article and Find Full Text PDFEffects of Clazakizumab on Anemia and Iron Metabolism in Patients with Kidney Failure.
J Am Soc Nephrol
May 2025
Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California.
Network meta-analysis of pharmacological treatment for antibody-mediated rejection after organ transplantation.
Front Immunol
December 2024
Institute of Transplantation Medicine, The Second Affiliated Hospital of Guangxi Medical University, Guangxi Clinical Research Center for Organ Transplantation, Guangxi Key Laboratory of Organ Donation and Transplantation, Nanning, Guangxi, China.
Objective: This study aims to assess the efficacy of pharmacological interventions in mitigating graft injury in transplant patients with antibody-mediated rejection (AMR) through a network meta-analysis (NMA).
Methods: A search was conducted on databases such as Cochrane Library, PubMed, EmBase, and Web of Science for randomized controlled trials (RCTs) on pharmacological interventions for alleviating graft injury following AMR. The search was performed for publications up to April 12, 2024.
New Therapies for Highly Sensitized Patients on the Waiting List.
Kidney360
August 2024
Transplant Center, Cedars-Sinai Medical Center, West Hollywood, California.
Article Synopsis
- * Traditional desensitization methods, like plasmapheresis and immunoglobulin therapy, struggle with removing persistent high-titer HLA antibodies, making them less effective for highly sensitized patients.
- * New strategies, including treatments like imlifidase and anti-IL-6 receptor agents, show promise in managing antibody response and improving transplant success by targeting long-lived immune cells and preventing antibody rebound.
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Nat Med
August 2024
Duke University, Durham, NC, USA.
Inflammation mediated by interleukin-6 (IL-6) is strongly associated with cardiovascular risk. Here we evaluated clazakizumab, a monoclonal antibody targeting the IL-6 ligand, in a phase 2b dose-finding study. Adults with cardiovascular disease and/or diabetes receiving maintenance dialysis with high-sensitivity C-reactive protein (hs-CRP) ≥ 2 mg l at baseline were randomized to receive clazakizumab (2.
View Article and Find Full Text PDF